AVEO - AVEO Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.22
-0.06 (-2.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.28
Open2.28
Bid2.20 x 4000
Ask2.28 x 1100
Day's Range2.19 - 2.30
52 Week Range0.63 - 4.24
Volume870,971
Avg. Volume1,707,980
Market Cap342.217M
Beta1.41
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected
    Zacks17 days ago

    AVEO Pharmaceuticals (AVEO) Q1 Loss Wider Than Expected

    AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the first quarter while revenues come almost in-line with estimates. Data from TIVO-3 study postponed. Shares down.

  • Market Exclusive17 days ago

    Here Is What Just Happened With Aveo Pharmaceuticals

    AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is attracting a substantial amount of attention in the biotechnology space early morning out of Europe this week, with the company moving on and update related to one of its lead development assets in the sector. Here is a look at what happened and why it is important for AVEO and […] The post Here Is What Just Happened With Aveo Pharmaceuticals appeared first on Market Exclusive.

  • Here's Why AVEO Pharmaceuticals Fell as Much as 17% Today
    Motley Fool18 days ago

    Here's Why AVEO Pharmaceuticals Fell as Much as 17% Today

    The company announced a delay concerning its top drug candidate.

  • AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
    Zacks26 days ago

    AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?

    AVEO Pharmaceuticals' (AVEO) first drug, Fotivda for the first-line treatment of RCC is likely to have a favorable impact on first-quarter results.

  • Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
    Zackslast month

    Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock

    Surging implied volatility makes AVEO Pharmaceuticals (AVEO) lucrative to the option traders.

  • AVEO Down 7.7% Since Earnings Report: Can It Rebound?
    Zackslast month

    AVEO Down 7.7% Since Earnings Report: Can It Rebound?

    AVEO reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Why AVEO Oncology Jumped Higher Today
    Motley Fool2 months ago

    Why AVEO Oncology Jumped Higher Today

    Investors see value after last week's decline.

  • Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)
    Zacks2 months ago

    Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)

    Moving Average Crossover Alert: AVEO Pharmaceuticals, Inc. (AVEO)

  • Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock
    Zacks2 months ago

    Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock

    AVEO Pharmaceuticals (AVEO) needs investors to pay close attention to the stock based on moves in the options market lately.

  • AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down
    Zacks2 months ago

    AVEO Pharmaceuticals (AVEO) Q4 Loss Widens, Shares Down

    AVEO Pharmaceuticals (AVEO) reports wider-than-expected loss in the fourth quarter with revenues missing estimates. The top line also declines year over year.

  • Associated Press2 months ago

    AVEO posts 4Q profit

    On a per-share basis, the Cambridge, Massachusetts-based company said it had profit of 8 cents. The cancer drug company posted revenue of $82,000 in the period. For the year, the company reported that ...

  • AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?
    Zacks3 months ago

    AVEO Pharmaceuticals' (AVEO) Q4 Earnings: What's in Store?

    AVEO Pharmaceuticals (AVEO) launched its first drug, Fotivda, as first-line treatment for RCC in Europe in November. This is likely to have a favorable impact on fourth-quarter results.

  • AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda
    Zacks3 months ago

    AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

    AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

  • How Much is AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO Getting Paid?
    Simply Wall St.4 months ago

    How Much is AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO Getting Paid?

    Michael Bailey took the helm as AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO and grew market cap to $363.25M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • Here's Why AVEO Oncology Rose as Much as 13.7% Today
    Motley Fool4 months ago

    Here's Why AVEO Oncology Rose as Much as 13.7% Today

    The company is fresh off a presentation at the J,P. Morgan Healthcare Conference.

  • Company Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Rounds Off Refinancing of Debt Facility with Hercules
    SmarterAnalyst5 months ago

    Company Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Rounds Off Refinancing of Debt Facility with Hercules

    AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) is wrapping up the refinancing of its existing debt facility with Hercules and affiliates: one with a $20 million tag. The terms of the refinancing will provide a roughly $12.1 million in cash flow over the course of this year and next when against the previous loan, and the AVEO corporate team is rejoicing that this will extend the runway into 2019. Proceeds of the new facility will be used to retire the Company’s existing $20.0 million of secured debt with Hercules.

  • Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
    Zacks5 months ago

    Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

    Investors in AVEO Pharmaceuticals (AVEO) need to pay close attention to the stock based on moves in the options market lately.

  • AVEO Pharmaceuticals, Inc. (AVEO) Continues to Build Strong Momentum in Its Oncology Programs
    SmarterAnalyst6 months ago

    AVEO Pharmaceuticals, Inc. (AVEO) Continues to Build Strong Momentum in Its Oncology Programs

    AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced updates on clinical development for FOTIVDA® (tivozanib), the Company’s potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors, and ficlatuzumab, the Company’s humanized IgG1 antibody that binds to the hepatocyte growth factor (HGF) ligand with high affinity and specificity to inhibit the biological activities of the HGF/c-Met pathway. Enrollment Complete in Phase 2 Portion of Phase 1/2 TiNivo Trial in Advanced RCC. AVEO announced today that enrollment of 21 patients is now complete, with one patient remaining in screening, in the Phase 2 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib in combination with Bristol-Myers Squibb’s OPDIVO® (nivolumab), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced RCC.

  • AVEO Pharmaceuticals, Inc. (AVEO) Names New Senior Vice President of Regulatory and Quality Assurance
    SmarterAnalyst6 months ago

    AVEO Pharmaceuticals, Inc. (AVEO) Names New Senior Vice President of Regulatory and Quality Assurance

    AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) today expanded its executive team by naming Nikhil Mehta, Ph.D. as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017. In this role, Dr. Mehta will oversee all aspects of regulatory, quality and technical operations for the company’s portfolio. Dr. Mehta brings to AVEO more than 25 years of experience in the biotechnology and pharmaceutical industries, having played a key role in the development and approval of important therapeutic products in the areas of oncology and orphan disease.

  • What’s Installed For AVEO Pharmaceuticals Inc (AVEO)?
    Simply Wall St.6 months ago

    What’s Installed For AVEO Pharmaceuticals Inc (AVEO)?

    AVEO Pharmaceuticals Inc (NASDAQ:AVEO), a USD$362.06M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such asRead More...

  • Cancer Space Update: Label Expansion for Three Major Drugs
    Zacks6 months ago

    Cancer Space Update: Label Expansion for Three Major Drugs

    This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

  • AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda
    Zacks7 months ago

    AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda

    AVEO Pharmaceuticals reported narrower-than-expected adjusted loss in the third quarter. Moreover, it received approval for its first drug, Fotivda, which was approved in EU for bladder cancer.

  • Company Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Provides 3Q:17 Update
    SmarterAnalyst7 months ago

    Company Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Provides 3Q:17 Update

    AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) reported financial results for the third quarter ended September 30, 2017 and provided a business update. Notably, with the European approval of tivozanib (FOTIVDA®) in advanced RCC, we have transitioned from a development stage company to one with a commercially approved product, a watershed achievement for any emerging life sciences company,” said Michael Bailey, president and chief executive officer of AVEO. “In addition, TIVO-3, our U.S. registration study, successfully passed the interim futility analysis with no changes to study protocol.

  • Associated Press7 months ago

    AVEO reports 3Q loss

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 22 cents. Losses, adjusted for non-recurring costs, came to 2 cents per share. The cancer drug company posted revenue ...

  • Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in October
    Motley Fool7 months ago

    Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in October

    The wild ride continues.